The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases

참고문헌 (181)

1. Ferguson, S. S., "Evolving concepts in G protein-coupled receptor endocytosis : the role in receptor desensitization and signaling", Pharmacol. Rev, 53, pp.1~24 (2001)
2. Ferguson, S. S., "Molecular mechanisms of G protein-coupled receptor desensitization and resensitization", Life Sci, 62, pp.1561~1565 (1998)
3. Ferguson, S. S., "Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization", Science, 271, pp.363~366 (1996)
4. Goodman, O. B. Jr, "Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor", Nature, 383, pp.447~450 (1996)
5. Shenoy, S. K., "beta-Arrestin-mediated receptor trafficking and signal transduction", Trends Pharmacol. Sci, 32, pp.521~533 (2011)
6. Zhang, J., "Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor inter nalization", J. Biol. Chem, 271, pp.18302~18305 (1996)
7. Lefkowitz, R. J., "A brief history of G-protein coupled receptors(Nobel Lecture)", Angew. Chem. Int. Ed. Engl, 52, pp.6366~6378 (2013)
8. Pitcher, J. A., "G protein-coupled receptor kinases", Annu. Rev. Biochem, 67, pp.653~692 (1998)
9. Zhang, M., "Loss of betaarrestin1 and betaarrestin2contributes to pulmonary hypoplasia and neonatal lethality in mice", Dev. Biol, 339, pp.407~417 (2010)
10. Bohn, L. M., "Enhanced morphine analgesia in mice lacking beta-arrestin 2", Science, 286, pp.2495~2498 (1999)
11. Conner, D. A., "beta-arrestin1 knockout mice appear normal but demon strate altered cardiac responses to beta-adrenergic stimulation", Circ. Res, 81, pp.1021~1026 (1997)
12. Feng, X., "beta-arestins : multifunctional signaling adaptors in type 2 diabetes", Mol. Biol. Rep, 38, pp.2517~2528 (2011)
13. van Gastel, J., "beta-arrestin based receptor signaling paradigms : potential therapeutic targets for complex age-related disorders", Front. Pharmacol, 9, pp.1369~ (2018)
14. Hirsch, J. A., "The 2.8 A crystal structure of visual arrestin: a model for arrestin’s regulation", Cell, 97, pp.257~269 (1999)
15. Hollingsworth, J. W., "Both hematopoietic-derived and non-hematopoietic derived {beta}-arrestin-2 regulates murine allergic airway disease", Am. J. Respir. Cell Mol. Biol, 43, pp.269~275 (2010)
16. Parruti, G., "Molecular analysis of human beta-arrestin-1: cloning, tissue distribution, and regulation of expression. Identification of two isoforms gen erated by alternative splicing", J. Biol. Chem, 268, pp.9753~9761 (1993)
17. Radin, J. N., "beta-arrestin 1 participates in platelet-activating factor receptor-mediated endocytosis of Streptococcus pneumoniae", Infect. Immun, 73, pp.7827~7835 (2005)
18. Zhan, X., "Crystal structure of arrestin-3 reveals the basis of the difference in receptor binding between two non-visual subtypes", J. Mol. Biol, 406, pp.467~478 (2011)
19. Jiang, D., "beta-Arrestins in the immune system", Prog. Mol. Biol. Transl. Sci, 118, pp.359~393 (2013)
20. Fan, X. L., "Differential regulation of beta-arrestin 1 and beta-arrestin 2 gene expression in rat brain by morphine", Neuroscience, 117, pp.383~389 (2003)
21. Gurevich, E. V., "Arrestin2 and arrestin3 are dif ferentially expressed in the rat brain during postnatal development", Neu roscience, 109, pp.421~436 (2002)
22. Grange-Midroit, M., "G protein-coupled receptor kinases, beta-arrestin-2 and associated regulatory proteins in the human brain : postmortem changes, effect of age and subcellular distribution", Brain Res. Mol. Brain Res, 101, pp.39~51 (2002)
23. Bychkov, E., "Distinct cellular and subcellular distributions of G protein-coupled receptor kinase and arrestin isoforms in the striatum", PLoS ONE, 7, pp.e48912~ (2012)
24. Urs, N. M., "Distinct cortical and striatal actions of a beta-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties", Proc. Natl Acad. Sci. USA, 113, pp.E8178~E8186 (2016)
25. Tao, Y., "Astroglial beta-arrestin1-mediated nuclear signaling regulates the expansion of neural precursor cells in adult hippocampus", Sci. Rep, 5, pp.15506~ (2015)
26. Hoeppner, C. Z., "Identification of a nuclear localization sequence in beta-arrestin-1 and its functional implications", J. Biol. Chem, 287, pp.8932~8943 (2012)
27. Oakley, R. H., "Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein coupled receptors delineate two major classes of receptors", J. Biol. Chem, 275, pp.17201~17210 (2000)
28. Wang, P., "Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus", J. Biol. Chem, 278, pp.11648~11653 (2003)
29. Scott, M. G., "Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2", J. Biol. Chem, 277, pp.37693~37701 (2002)
30. Gurevich, V. V., "GPCR signaling regulation : the role of GRKs and arrestins", Front. Pharmacol, 10, pp.125~ (2019)
31. Gurevich, V. V., "Arrestin interactions with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, beta 2-adre nergic, and m2 muscarinic cholinergic receptors", J. Biol. Chem, 270, pp.720~731 (1995)
32. Foord, S. M., "International Union of Pharmacology. XLVI. G protein-coupled receptor list", Pharmacol. Rev, 57, pp.279~288 (2005)
33. Ghosh, E., "Methodological advances : the unsung heroes of the GPCR structural revolution", Nat. Rev. Mol. Cell Biol, 16, pp.69~81 (2015)
34. Lee, Y., "Recent advances in structure-based drug design targeting class A G protein-coupled receptors utilizing crystal structures and computational simulations", J. Med. Chem, 61, pp.1~46 (2018)
35. Hu, G. M., "Visualizing the GPCR network : classification and evolution", Sci. Rep, 7, pp.15495~ (2017)
36. Ahn, S., "Desensitiza tion, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference", Proc. Natl Acad. Sci. USA, 100, pp.1740~1744 (2003)
37. Kohout, T. A., "beta-arrestin 1and 2 differentially regulate heptahelical receptor signaling and trafficking", Proc. Natl Acad. Sci. USA, 98, pp.1601~1606 (2001)
38. Macey, T. A., "Preferential interaction between the dopamine D2 receptor and arrestin2 in neostriatal neurons", Mol. Pharmacol, 66, pp.1635~1642 (2004)
39. Macey, T. A., "Dopamine D1 receptor inter action with arrestin3 in neostriatal neurons", J. Neurochem, 93, pp.128~134 (2005)
40. Bohn, L. M., "Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence", Nature, 408, pp.720~723 (2000)
41. Celver, J. P., "Threonine 180 is required for G-protein-coupled receptor kinase 3-and beta-arrestin 2-mediated desensitization of the mu-opioid receptor in Xenopus oocytes", J. Biol. Chem, 276, pp.4894~4900 (2001)
42. Dang, V. C., "Cellular morphine tolerance produced by betaarrestin-2-dependent impairment of mu-opioid receptor resensitization", J. Neurosci, 31, pp.7122~7130 (2011)
43. Groer, C. E., "Agonist-directed interac tions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation", J. Biol. Chem, 286, pp.31731~31741 (2011)
44. Kovoor, A., "Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy", Mol. Pharmacol, 54, pp.704~711 (1998)
45. Kovoor, A., "Mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in Xenopus oocytes", J. Biol. Chem, 272, pp.27605~27611 (1997)
46. Markova, V., "beta-arrestin 1 and 2 similarly influence mu-opioid receptor mobility and distinctly modulate ade nylyl cyclase activity", Cell Signal, 87, pp.110124~ (2021)
47. Pradhan, A. A., "Agonist-specific recruitment of arrestin isoforms differen tially modify delta opioid receptor function", J. Neurosci, 36, pp.3541~3551 (2016)
48. Kang, J., "A nuclear function of beta-arrestin1 in GPCR signaling : regulation of histone acetylation and gene transcription", Cell, 123, pp.833~847 (2005)
49. Sanni, S. J., "beta-arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations", Br. J. Pharmacol, 161, pp.150~161 (2010)
50. Jones, K. T., "Agonist mediated internalization of M2 mAChR is beta-arrestin-dependent", J. Mol. Signal, 1, pp.7~ (2006)
51. Haider, R. S., "beta-arrestin1 and 2 exhibit distinct phosphorylation dependent conformations when coupling to the same GPCR in living cells", Nat. Commun, 13, pp.5638~ (2022)
52. Luttrell, L. M., "The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals", J. Cell Sci, 115, pp.455~465 (2002)
53. Lefkowitz, R. J., "Transduction of receptor signals by beta-arrestins", Science, 308, pp.512~517 (2005)
54. Bouvier, M., "Removal of phosphorylation sites from the beta 2-adrenergic receptor delays onset of agonist-promoted desensitization", Nature, 333, pp.370~373 (1988)
55. Krupnick, J. G., "Arrestin", clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus, 1997, pp.272, 15011~15016
56. Laporte, S. A., "The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits", J. Biol. Chem, 275, pp.23120~23126 (2000)
57. Moo, E. V., "Arrestin dependent and-independent internalization of G protein-coupled receptors : methods, mechanisms, and implications on cell signaling", Mol. Pharmacol, 99, pp.242~255 (2021)
58. Schmid, E. M., "Role of the AP2 beta-appendage hub in recruiting partners for clathrin-coated vesicle assembly", PLoS Biol, 4, pp.e262~ (2006)
59. Kang, D. S., "Structure of an arrestin2-clathrin complex reveals a novel clathrin binding domain that modulates receptor trafficking", J. Biol. Chem, 284, pp.29860~29872 (2009)
60. Nobles, K. N., "The active con formation of beta-arrestin1 : direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of beta-arrestins1and-2", J. Biol. Chem, 282, pp.21370~21381 (2007)
61. Xiao, K., "Activation-dependent con formational changes in beta-arrestin 2", J. Biol. Chem, 279, pp.55744~55753 (2004)
62. Lin, F. T., "Feedback regulation of beta-arrestin1 function by extracellular signal-regulated kinases", J. Biol. Chem, 274, pp.15971~15974 (1999)
63. Lin, F. T., "Clathrin-mediated endocytosis of the beta-adrenergic receptor is regulated by phosphorylation", dephosphorylation of beta-arrestin1, 1997, pp.272, 31051~31057
64. Shenoy, S. K., "Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin", Science, 294, pp.1307~1313 (2001)
65. Krasel, C., "Beta-arrestin binding to the beta2-adrenergic receptor requires both receptor phosphorylation and receptor activation", J. Biol. Chem, 280, pp.9528~9535 (2005)
66. Reiter, E., "Molecular mechanism of beta arrestin-biased agonism at seven-transmembrane receptors", Annu. Rev. Phar macol. Toxicol, 52, pp.179~197 (2012)
67. Violin, J. D., "Beta-arrestin-biased ligands at seven transmembrane receptors", Trends Pharmacol. Sci, 28, pp.416~422 (2007)
68. Drake, M. T., "beta-arrestin-biased agonism at the beta2-adrenergic recep tor", J. Biol. Chem, 283, pp.5669~5676 (2008)
69. Hodavance, S. Y., "G protein-coupled receptor biased agonism", J. Cardiovasc. Pharmacol, 67, pp.193~202 (2016)
70. Liu, X., "beta-arrestin-biased signaling mediates memory reconsolidation", Proc. Natl Acad. Sci. USA, 112, pp.4483~4488 (2015)
71. Allen, J. A., "Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy", Proc. Natl Acad. Sci. USA, 108, pp.18488~18493 (2011)
72. Chen, X., "Structure-functional selectivity relationship studies of beta-arrestin biased dopamine D(2)receptor agonists", J. Med Chem, 55, pp.7141~7153 (2012)
73. Xiao, K., "Functional specialization of beta-arrestin interactions revealed by proteomic analysis", Proc. Natl Acad. Sci. USA, 104, pp.12011~12016 (2007)
74. Zhuo, Y., "A non GPCR-binding partner interacts with a novel surface on beta-arrestin1 to mediate GPCR signaling", J. Biol. Chem, 295, pp.14111~14124 (2020)
75. Shukla, A. K., "Arresting a transient receptor potential(TRP)channel : beta arrestin 1 mediates ubiquitination and functional down-regulation of TRPV4", J. Biol. Chem, 285, pp.30115~30125 (2010)
76. Lefkowitz, R. J., "New roles for beta-arrestins in cell signaling : not just for seven-transmembrane receptors", Mol. Cell, 24, pp.643~652 (2006)
77. Por, E. D., "beta-arrestin-2 desensitizes the transient receptor potential vanilloid 1(TRPV1)channel", J. Biol. Chem, 287, pp.37552~37563 (2012)
78. Chen, G., "beta-arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain", Nat. Commun, 7, pp.12531~ (2016)
79. Collingridge, G. L., "Long-term depres sion in the CNS", Nat. Rev. Neurosci, 11, pp.459~473 (2010)
80. Fan, X., "The NMDA receptor complex : a multifunctional machine at the glutamatergic synapse", Front. Cell. Neurosci, 8, pp.160~ (2014)
81. Chen, W., "Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling", Science, 301, pp.1394~1397 (2003)
82. Perry, N. A., "Arrestin-3 interaction with maternal embryonic leucine-zipper kinase", Cell Signal, 63, pp.109366~ (2019)
83. Kovacs, J. J., "Beta-arrestin-mediated localization of smoothened to the primary cilium", Science, 320, pp.1777~1781 (2008)
84. Storez, H., "Homo-and hetero-oligomerization of beta-arrestins in living cells", J. Biol. Chem, 280, pp.40210~40215 (2005)
85. Milano, S. K., "Nonvisual arrestin oligomerization and cellular localization are regulated by inositol hex akisphosphate binding", J. Biol. Chem, 281, pp.9812~9823 (2006)
86. Boularan, C., "beta-arrestin 2 oligomerization controls the Mdm2-dependent inhibition of p53", Proc. Natl Acad. Sci. USA, 104, pp.18061~18066 (2007)
87. Woo, J. A., "beta-arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates", Proc. Natl Acad. Sci. USA, 117, pp.5006~5015 (2020)
88. Woo, J. A., "beta-arrestin1 promotes tauopathy by transducing GPCR sig naling, disrupting microtubules and autophagy", Life Sci. Alliance (2022)[DOI]
89. Hardy, J., "The amyloid hypothesis of Alzheimer’s disease : progress and problems on the road to therapeutics", Science, 297, pp.353~356 (2002)
90. Bossers, K., "Concerted changes in transcripts in the prefrontal cortex pre cede neuropathology in Alzheimer’s disease", Brain, 133, pp.3699~3372 (2010)
91. Liu, X., "β-Arrestin1 regulates γ-secretase complex assembly and modulates amyloid-β pathology", Cell Res, 23, pp.351~365 (2013)
92. Thathiah, A., "β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer’s disease", Nat. Med, 19, pp.43~49 (2013)
93. Liu, Y., "Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes", J. Pathol, 225, pp.54~62 (2011)
94. Todd, N. K., "GPCR kinases generate an APH1A phosphorylation barcode to regulate amyloid-beta generation", Cell Rep, 40, pp.111110~ (2022)
95. Ni, Y., "Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation", Nat. Med, 12, pp.1390~1396 (2006)
96. Pasternak, S. H., "Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane", J. Biol. Chem, 278, pp.26687~26694 (2003)
97. Wang, D., "Amyloid beta peptide-(1-42)induces internalization and degradation of beta2 adrenergic receptors in pre frontal cortical neurons", J. Biol. Chem, 286, pp.31852~31863 (2011)
98. Thathiah, A., "The orphan G protein-coupled receptor 3 modulates amyloid beta peptide generation in neurons", Science, 323, pp.946~951 (2009)
99. Nelson, C. D., "Gpr3 stimulates Aβ production via interactions with APP and β-arrestin2", PLoS ONE, 8, pp.e74680~ (2013)
100. Huang, Y., "G protein-biased GPR3 signaling ameliorates amyloid pathology in a preclinical Alzheimer’s disease mouse model", Proc. Natl Acad. Sci. USA, 119, pp.e2204828119~ (2022)
101. Haque, M. E., "Importance of GPCR mediated microglial activation in Alzheimer’s disease", Front. Cell Neurosci, 12, pp.258~ (2018)
102. Thathiah, A., "The role of G protein-coupled receptors in the pathology of Alzheimer’s disease", Nat. Rev. Neurosci, 12, pp.73~87 (2011)
103. Obrenovich, M. E., "The GRK2overexpression is a primary hallmark of mitochondrial lesions during early Alzheimer disease", Cardiovasc. Psychiatry Neurol, 2009, pp.327360~ (2009)
104. Suo, Z., "Abnormality of G protein-coupled receptor kinases at prodromal and early stages of Alzheimer’s disease : an association with early beta-amyloid accumulation", J. Neurosci, 24, pp.3444~3452 (2004)
105. Zhang, Y., "GRK5 dysfunction accelerates tau hyperphosphorylation in APP(swe)mice through impaired cholinergic activity", Neuroreport, 25, pp.542~547 (2014)
106. Suo, W. Z., "Dysfunction of G protein-coupled receptor kinases in Alz heimer’s disease", ScientificWorldJournal, 10, pp.1667~1678 (2010)
107. Wu, H., "Abeta monomer induces phosphorylation of tau at Ser-214 through beta2AR-PKA-JNK signaling pathway", FASEB J, 34, pp.5092~5105 (2020)
108. Sharma, K., "Cholinesterase inhibitors as Alzheimer’s therapeutics(Review)", Mol. Med. Rep, 20, pp.1479~1487 (2019)
109. Olivares, D., "N-methyl D-aspartate(NMDA)receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkin son’s disease", Curr. Alzheimer Res, 9, pp.746~758 (2012)
110. Shi, M., "Impact of anti-amyloid-beta monoclonal anti bodies on the pathology and clinical profile of Alzheimer’s disease : a focus on aducanumab and lecanemab", Front. Aging Neurosci, 14, pp.870517~ (2022)
111. "Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups", J. Neurol. Neurosurg. Psychiatry, 57, pp.416~418 (1994)
112. Arnold, S. E., "Quanti tative neurohistological features of frontotemporal degeneration", Neurobiol. Aging, 21, pp.913~919 (2000)
113. Cairns, N. J., "Neuropathologic diagnostic and nosologic criteria for fron totemporal lobar degeneration : consensus of the Consortium for Fronto temporal Lobar Degeneration", Acta Neuropathol, 114, pp.5~22 (2007)
114. Tsai, R. M., "Treatment of frontotemporal dementia", Curr. Treat. Options Neurol, 16, pp.319~ (2014)
115. Beitz, J. M., "Parkinson’s disease : a review", Front Biosci. (Schol. Ed. ), 6, pp.65~74 (2014)
116. Driver, J. A., "Incidence and remaining lifetime risk of Parkinson disease in advanced age", Neurology, 72, pp.432~438 (2009)
117. Dorsey, E. R., "Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030", Neurology, 68, pp.384~386 (2007)
118. Pringsheim, T., "The prevalence of Parkinson’s disease : a systematic review and meta-analysis", Mov. Disord, 29, pp.1583~1590 (2014)
119. De Virgilio, A., "Parkinson’s disease : autoimmunity and neuroinflammation", Autoimmun. Rev, 15, pp.1005~1011 (2016)
120. Lerner, A., "Olfactory pathogenesis of idiopathic Parkinson disease revisited", Mov. Disord, 23, pp.1076~1084 (2008)
121. Goedert, M., "100 years of Lewy pathology", Nat. Rev. Neurol, 9, pp.13~24 (2013)
122. Azam, S., "-protein-coupled receptors in CNS: a potential therapeutic target for intervention in neurodegenerative disorders and associated cognitive deficits", Cells (2020)[DOI]
123. Mattila, S. O., "The Parkinson’s-disease-associated receptor GPR37 undergoes metalloproteinase-mediated N-terminal cleavage and ectodomain shedding", J. Cell Sci, 129, pp.1366~1377 (2016)
124. Gu, C., "Role of G protein-coupled receptors in microglial activation : implication in Parkinson’s disease", Front. Aging Neurosci, 13, pp.768156~ (2021)
125. McGeer, P. L., "Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s dis ease brains", Neurology, 38, pp.1285~1291 (1988)
126. Fang, Y., "Opposing functions of beta-arrestin 1 and 2 in Parkinson’s disease via microglia inflammation and Nprl3", Cell Death Differ, 28, pp.1822~1836 (2021)
127. Loniewski, K., "Toll-like receptors differen tially regulate GPCR kinases and arrestins in primary macrophages", Mol. Immunol, 45, pp.2312~2322 (2008)
128. Fong, A. M., "Defective lymphocyte chemotaxis in beta-arrestin2-and GRK6deficient mice", Proc. Natl Acad. Sci. USA, 99, pp.7478~7483 (2002)
129. Wang, G., "Effects of beta-arrestin 2 on cytokine production of CD4+ T lymphocytes of mice with allergic asthma", Indian J. Exp. Biol, 49, pp.585~593 (2011)
130. Volta, M., "Elevated levels of alpha-synuclein blunt cellular signal trans duction downstream of Gq protein-coupled receptors", Cell Signal, 30, pp.82~91 (2017)
131. Mittal, S., "beta2-adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease", Science, 357, pp.891~898 (2017)
132. Beaulieu, J. M., "An Akt", beta-arrestin 2, Cell, pp.2005, 122[DOI]
133. Bezard, E., "L-DOPA reverses the MPTP-induced elevation of the arrestin2and GRK6 expression and enhanced ERK activation in monkey brain", Neurobiol. Dis, 18, pp.323~335 (2005)
134. Bychkov, E. R., "Arrestins and two receptor kinases are upregulated in Parkinson’s disease with dementia", Neurobiol. Aging, 29, pp.379~396 (2008)
135. Pronin, A. N., "Synucleins are a novel class of substrates for G protein-coupled receptor kinases", J. Biol. Chem, 275, pp.26515~26522 (2000)
136. Tambasco, N., "Levodopa in Parkinson’s disease : cur rent status and future developments", Curr. Neuropharmacol, 16, pp.1239~1252 (2018)
137. Lu, J., "Dopamine D2 receptor and beta-arrestin 2mediate amyloid-beta elevation induced by anti-parkinson’s disease drugs, levodopa and piribedil, in neuronal cells", PLoS ONE, 12, pp.e0173240~ (2017)
138. Peihua, L., "Clinical effects of piribedil in adjuvant treatment of Parkinson’s disease : a meta-analysis", Open Med, 13, pp.270~277 (2018)
139. Mizuno, Y., "Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease", Mov. Disord, 28, pp.1138~1141 (2013)
140. Luquin, M. R., "Levodopa induced dyskinesias in Parkinson’s disease : clinical and pharmacological classi f ication", Mov. Disord, 7, pp.117~124 (1992)
141. Bargiotas, P., "Levodopa-induced dyskinesias in Parkinson’s dis ease: emerging treatments", Neuropsychiatr. Dis. Treat, 9, pp.1605~1617 (2013)
142. Ahlskog, J. E., "Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature", Mov. Disord, 16, pp.448~458 (2001)
143. Darmopil, S., "Genetic inac tivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyski nesia and histone activation", Biol. Psychiatry, 66, pp.603~613 (2009)
144. Zhang, X. R., "beta-arrestin2 alleviates L-dopa-induced dyskinesia via lower D1R activity in Parkinson’s rats", Aging, 11, pp.12315~12327 (2019)
145. Di Monte, D. A., "Relationship among nigrostriatal denervation, Parkinson ism, and dyskinesias in the MPTP primate model", Mov. Disord, 15, pp.459~466 (2000)
146. Shenoy, S. K., "Multifaceted roles of beta-arrestins in the reg ulation of seven-membrane-spanning receptor trafficking and signalling", Bio chem J, 375, pp.503~515 (2003)
147. Benovic, J. L., "Beta-adrenergic receptor kinase : identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor", Proc. Natl Acad. Sci. USA, 83, pp.2797~2801 (1986)
148. Urs, N. M., "Targeting beta-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease", Proc. Natl Acad. Sci. USA, 112, pp.E2517~E2526 (2015)
149. Simola, N., "The 6-hydroxydopamine model of Parkin son’s disease", Neurotox. Res, 11, pp.151~167 (2007)
150. Lim, E. W., "Amyloid-beta and Parkinson’s disease", J. Neurol, 266, pp.2605~2619 (2019)
151. Lu, J., "An anti-Parkinson’s disease drug via targeting adenosine A2A receptor enhances amyloid-beta generation and gamma-secretase activity", PLoS ONE, 11, pp.e0166415~ (2016)
152. Komatsu, M., "Loss of autophagy in the central nervous system causes neurodegeneration in mice", Nature, 441, pp.880~884 (2006)
153. Nixon, R. A., "The role of autophagy in neurodegenerative disease", Nat. Med, 19, pp.983~997 (2013)
154. Alvarez-Erviti, L., "Chaperone-mediated autophagy markers in Parkinson disease brains", Arch. Neurol, 67, pp.1464~1472 (2010)
155. McNaught, K. S., "Proteasomal function is impaired in substantia nigra in Parkinson’s disease", Neurosci. Lett, 297, pp.191~194 (2001)
156. Vogiatzi, T., "Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells", J. Biol. Chem, 283, pp.23542~23556 (2008)
157. Bancher, C., "Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer’s and Parkinson’s disease patients", Neurosci. Lett, 162, pp.179~182 (1993)
158. Joachim, C. L., "Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders", Ann. Neurol, 22, pp.514~520 (1987)
159. Lei, P., "Tau protein : relevance to Parkinson’s disease", Int J. Biochem. Cell Biol, 42, pp.1775~1778 (2010)
160. Singh, B., "Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of alpha-synucleinopathy", Acta Neuropathol, 138, pp.551~574 (2019)
161. Hulisz, D., "Amyotrophic lateral sclerosis : disease state overview", Am. J. Manag. Care, 24, pp.S320~S326 (2018)
162. Masrori, P., "Amyotrophic lateral sclerosis : a clinical review", Eur. J. Neurol, 27, pp.1918~1929 (2020)
163. Goetz, C. G., "Amyotrophic lateral sclerosis : early contributions of Jean-Martin Charcot", Muscle Nerve, 23, pp.336~343 (2000)
164. Doble, A, "The pharmacology and mechanism of action of riluzole", Neurology, 47, pp.S233~241 (1996)
165. Hubert, J. P., "Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action", Br. J. Pharmacol, 113, pp.261~267 (1994)
166. Writing, G., "Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial", Lancet Neurol, 16, pp.505~512 (2017)
167. Rosen, D. R., "Mutations in Cu", Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, 1993, pp.362, 59~62
168. Zhang, S., "Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis", Neuron, 110, pp.992~1008 (2022)
169. Buratti, E., "Functional significance of TDP-43 mutations in disease", Adv. Genet, 91, pp.1~53 (2015)
170. Morgan, S., "Pathogenesis of amyotrophic lateral sclerosis", Br. Med. Bull, 119, pp.87~98 (2016)
171. Neumann, M., "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis", Science, 314, pp.130~133 (2006)
172. Trieu, V. N., "A specific inhibitor of Janus kinase-3increases survival in a transgenic mouse model of amyotrophic lateral sclerosis", Biochem. Biophys. Res. Commun, 267, pp.22~25 (2000)
173. Guo, W., "The mul tifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications", Brain, 143, pp.1651~1673 (2020)
174. Paik, H., "Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records", Sci. Rep, 5, pp.8580~ (2015)
175. Teng, Y. D., "Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis", Neurosci. Lett, 397, pp.155~158 (2006)
176. Bartus, R. T., "beta2-Adrenoceptor agonists as novel, safe and potentially effective therapies for amyotrophic lateral sclerosis(ALS)", Neurobiol. Dis, 85, pp.11~246 (2016)
177. Joassard, O. R., "beta2-adrenergic agonists and the treatment of skeletal muscle wasting disorders", Int J. Biochem. Cell Biol, 45, pp.2309~2321 (2013)
178. Hu, W. T., "TDP-43 and frontotemporal dementia", Curr. Neurol. Neurosci. Rep, 9, pp.353~358 (2009)
179. Vishnivetskiy, S. A., "Mapping the arrestin-receptor interface. Structural elements responsible for receptor speci f icity of arrestin proteins", J. Biol. Chem, 279, pp.1262~1268 (2004)
180. Littmann, T., "Recruitment of beta-arrestin 1 and 2 to the beta2-adreno ceptor : analysis of 65 ligands", J. Pharmacol. Exp. Ther, 355, pp.183~190 (2015)
181. Huang, J. Z., "The delta-opioid receptor and Parkinson’s disease", CNS Neu rosci. Ther, 24, pp.1089~1099 (2018)

관련 논문AI추천